View Document Preview and Link Document Date: 2000-02-23 09:53:55 Open Document File Size: 41,50 KB Share Result on Facebook
Event Person Communication and Meetings / / IndustryTerm direct product / treatment of a patient’s symptoms / treatment of neuropsychiatric symptoms / / MedicalCondition Alzheimer’s disease / schizophrenia / Dementia / disease / hallucinations / misidentification syndrome / schizoaffective disorder / cognitive impairment / mania / disorientation / dementias / delusional disorder / psychoses / mood disorder / delirium / prosopagnosia / each syndrome / memory loss / dementia syndrome / different disease / depression / Capgras syndrome / behavioral disorders / syndrome / bipolar disorder / / MedicalTreatment Pharmacotherapy / drug therapy / / Organization Food and Drug Administration / Psychopharmalogic Drugs Advisory Committee on the Various Psychiatric and Behavioral Disturbances Associated / FDA Advisory Committee / Division of Neuropharmacological Drug Products / Advisory Committee / Alzheimer’s Disease Center / UCLA School / / Person All / Jeffrey L. Cummings / Jeste / Alzheimer / / Position Director / observer / / Technology Drug Development / / SocialTag 
[removed]Written Statement for FDA Advisory Committee Meeting on Drug Development for Treating Psychiatric Disturbances Associated with Dementias Submitted by Jeffrey L. Cummings, M.D., Director, Alzheimer’s Disease Ce